*ST赛隆: 关于补选公司第四届董事会董事的公告

Core Viewpoint - The company, SAILONG Pharmaceutical Group Co., Ltd., has announced the nomination of candidates for both non-independent and independent directors to be elected at the upcoming shareholders' meeting, ensuring compliance with relevant laws and regulations [1][2]. Summary by Category Non-Independent Directors - The board has approved the nomination of five candidates for non-independent directors: Mr. Jia Jinbin, Mr. Chen Ke, Mr. Chen Dunfei, Mr. Zhang Guangyang, and Ms. Li Tongyao, with their terms starting from the date of election by the shareholders [1][2]. - All nominated non-independent directors do not hold shares in the company and have no relationships with shareholders holding more than 5% of the company's shares [3][4][6][10]. Independent Directors - The board has also approved the nomination of three candidates for independent directors: Ms. Wang Shufang, Mr. Zhang Jianmin, and Mr. Zhang Kai, pending approval at the shareholders' meeting [1][2]. - The independent director candidates have obtained the necessary qualifications and training, with Ms. Wang Shufang already holding an independent director qualification certificate [2][11][12][13]. - The election process will follow a cumulative voting system, and the independent directors must be filed with the Shenzhen Stock Exchange without objection before being submitted for shareholder approval [2]. Compliance and Qualifications - All nominated candidates meet the legal and regulatory requirements for their positions, including not having any penalties from regulatory bodies or being listed as untrustworthy by the courts [3][4][11][12][13]. - The company ensures that the number of independent directors will be no less than one-third of the total board members, and no independent director will have served more than six consecutive years [2].